BPIM
MRVI icon

Brant Point Investment Management’s Maravai LifeSciences MRVI Stock Holding History

Brant Point Investment Management’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-27,600
Closed -$1.35M – 135
2021
Q3 		$1.35M Buy
+27,600
New +$1.35M 0.12% 113

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
OCBV
Ownership Capital B.V. Amsterdam, Netherlands $178M AUM 4.75% 1-Year Est. Return

Brant Point Investment Management's MRVI Position: Q1 2021 in Review

Brant Point Investment Management sold out of Maravai LifeSciences (MRVI) in Q1 2021, closing a stake of 239,175 shares — an estimated $6.71M sold.

Brant Point Investment Management first reported a position in MRVI in Q4 2020 and held it in 1 quarter. The position peaked at $6.71M in Q4 2020. 144 funds tracked by Wall St. Rank hold MRVI as of Q1 2021.

  • Brant Point Investment Management reported no remaining Maravai LifeSciences position as of Q1 2021 after selling out during the quarter.
  • Brant Point Investment Management sold 239,175 Maravai LifeSciences shares in Q1 2021, an estimated $6.71M.
  • Brant Point Investment Management first reported a position in Maravai LifeSciences in Q4 2020 and held it in 1 quarter.
  • Brant Point Investment Management's Maravai LifeSciences position peaked at $6.71M in Q4 2020.
  • 144 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q1 2021.

Based on Brant Point Investment Management's 13F filing for Q1 2021, filed 14 May 2021.